MarketCap
SELLAS Life Sciences Group SLS
$ 13.86
1.17%
Facebook
X
Telegram
SELLAS Life Sciences Group EV - Enterprise Value | SLS
Annual EV - Enterprise Value SELLAS Life Sciences Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 503 M | 314 M | 39.7 M | 25.7 M | 79 M | 23.8 M | 10.2 M | 25.4 M | 44.6 M | 36 M | 143 M | 211 M | 522 M | 107 M | 7.67 M | 2.06 T | -5.68 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.06 T | -5.68 M | 121 B |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
59.3 B | - | - | - |  Russia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M |  USA |
 |
Завод ДИОД
DIOD
|
3.14 B | - | - | - | Russia |
 |
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Cleveland BioLabs, Inc.
CBLI
|
-29.8 M | - | -7.31 % | $ 49 M | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
880 M | - | - | $ 1.77 B | USA |
 |
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.42 B | - | -6.81 % | $ 3.04 B | USA |
 |
Biofrontera AG
BFRA
|
744 M | - | -8.24 % | $ 105 M |  Germany |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
168 B | - | -6.97 % | $ 657 M | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
15.4 B | - | 1.68 % | $ 4.65 B |  China |
 |
Flexion Therapeutics, Inc.
FLXN
|
1.49 B | - | - | $ 459 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
4.26 B | - | -5.76 % | $ 99.8 M | USA |
 |
Kindred Biosciences, Inc.
KIN
|
20.2 B | - | 0.11 % | $ 419 M | USA |
 |
Shineco, Inc.
TYHT
|
22.9 B | - | -3.90 % | $ 97.2 M | China |
 |
Millendo Therapeutics, Inc.
MLND
|
31.7 B | - | -5.36 % | $ 20.2 M | USA |
 |
Intec Pharma Ltd
NTEC
|
2.88 B | - | -12.45 % | $ 17.7 M |  Israel |
 |
Progenity, Inc.
PROG
|
225 M | - | -3.47 % | $ 164 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
664 M | - | - | $ 1.2 B | USA |
 |
Strongbridge Biopharma plc
SBBP
|
32.8 B | - | 1.52 % | $ 136 M | USA |
 |
Decibel Therapeutics
DBTX
|
109 M | - | - | $ 123 M | USA |
 |
Seneca Biopharma, Inc.
SNCA
|
2.82 B | - | -1.19 % | $ 28.7 M | USA |
 |
IVERIC bio
ISEE
|
2.62 B | - | - | $ 5.51 B | USA |
 |
Myovant Sciences Ltd.
MYOV
|
587 M | - | -0.04 % | $ 2.62 B | USA |
 |
Trean Insurance Group
TIG
|
1.47 B | - | - | $ 316 M | USA |
 |
Virpax Pharmaceuticals
VRPX
|
1.81 M | - | -45.12 % | $ 2.85 M | USA |
 |
Metacrine
MTCR
|
-35.4 M | - | - | $ 24.2 M | USA |
 |
Celsion Corporation
CLSN
|
-3.55 M | - | -6.63 % | $ 13.9 M | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
AnaptysBio
ANAB
|
1.28 B | $ 56.8 | 0.94 % | $ 1.63 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
174 M | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
-376 M | - | - | $ 867 M | Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
686 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
5.18 B | - | - | $ 4.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | Britain |
 |
MorphoSys AG
MOR
|
2.44 B | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
-38.5 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
215 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-1.83 M | - | - | $ 12.5 M |  Belgium |
 |
Gracell Biotechnologies
GRCL
|
-1.17 B | - | - | $ 3.37 B | China |
 |
Galapagos NV
GLPG
|
1.99 B | - | - | $ 1.83 B | Belgium |
 |
Teligent, Inc.
TLGT
|
4.75 B | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
5.37 B | - | - | $ 2.91 B | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
Aphria Inc.
APHA
|
54.3 B | - | -0.45 % | $ 4.87 B | Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
3.74 B | - | -0.90 % | $ 104 M | USA |